Treatment for patients with non-small cell lung cancer (NSCLC) is being guided increasingly by driver mutations and, routinely, tumors from patients with adenocarcinoma are screened for mutations in the kinase domain of the epidermal growth factor receptor (EGFR) as well as for other genomic abnormalities (i.e. anaplastic lymphoma kinase [ALK] and ROS1 translocations). Effective, well-tolerated treatment options that specifically target the EGFR T790M mutation (the "gatekeeper" residue) in patients with NSCLC remains an unmet need. Rociletinib is an oral, irreversible, potent, covalent inhibitor of the activating EGFR mutations (del19 and L858R) and the T790M resistance mutation; it also spares wild-type EGFR. TIGER-X is the first of the TIGER trial series, which is a clinical development program for rociletinib in patients with mutant EGFR NSCLC. This phase I-II study is evaluating rociletinib in patients who have progressed following their first and only EGFR-directed tyrosine kinase inhibitor (TKI) therapy who have developed the T790M mutation and in later-line T790M positive patients who have progressed on their second or later TKI therapy or subsequent chemotherapy. In the ongoing TIGER-X study, rociletinib has shown encouraging activity in patients with EGFR mutant-positive NSCLC and is well tolerated. Future aims of the ongoing TIGER programme include to investigate rociletinib treatment in other lines of therapy, determine whether rociletinib treatment can lead to an improvement in overall survival (OS) and to explore the potential benefits of combining rociletinib with other anti-cancer agents such as anti-programmed cell death protein and programmed cell death 1 ligand 1 monoclonal antibodies, mitogen-activated protein kinase enzyme inhibitors, vascular endothelial growth factor inhibitors, and c-Met inhibitors. Other aims include evaluating the outcome of progression-free survival associated with rociletinib treatment and determining the efficacy of rociletinib in patients with T790M negative status.
In 2015, the prevalence of patients living with lung cancer in the US is more than 430,000 and the incidence of new cases of lung cancer is around 221,200. 1 Deaths from lung cancer are estimated to be 158,040. 1 In Europe, in 2012, 410,000 patients were diagnosed with lung cancer and 354,000 died from the disease. 2, 3 Data from the National Lung Cancer Audit (LUCADA) for England in 2011 show that the majority of lung cancers (87 %) are classified as non small cell lung cancer (NSCLC). 4 Treatment decisions for patients with adenocarcinoma, which account for around 40 % of lung cancers, are increasingly being made based on driver mutations and other genomic abnormalities (i.e. anaplastic lymphoma kinase [ALK] and ROS1 translocations). Driver mutations are causally implicated in oncogenesis, confer a growth advantage to cancer cells, and are positively selected in the microenvironment of the cancer tissue. 5 Tumors from patients with advanced NSCLC are screened routinely for mutations in the kinase domain of the epidermal growth factor receptor (EGFR). Somatic EGFR mutations occur in approximately 10-30 % of patients with NSCLC 6 and are around twice as common in East Asian patients compared with Western patients. 7 The majority (approximately 90 %) of EGFR-mutation-positive patients have one of two types of activating mutations at the time of diagnosis -a deletion in exon 19 or an L858R point mutation in exon 21. 7 The first-and second-generation EGFR tyrosine kinase inhibitors (TKIs), gefitinib, 8 erlotinib, 9 and afatinib 10 are effective against lung cancers with these mutations; however, acquired resistance develops within a median of 9 to 13 months, limiting their duration of efficacy. Acquired resistance of NSCLC to EGFR TKIs develops through various molecular mechanisms, principally T790M secondary mutation, but also MET amplification, hepatocyte growth factor (HGF) overexpression, PTEN downregulation, and epithelial-mesenchymal transition (EMT) among others. 11 Most commonly, however, this resistance is due to the EGFR T790M mutation (the "gatekeeper" residue), which is present in around 50-60 % of resistant cases. 12, 13 This mutation occurs in the adenosine triphosphate (ATP) binding site of the kinase 14 and leads to a raised affinity for ATP, thereby reducing the ability of ATP-competitive reversible EGFR tyrosine TKIs to bind to the tyrosine kinase domain of EGFR. 15 Wild-type EGFR inhibition can lead to cutaneous toxicity and diarrhoea. 16 The median survival after the emergence of the T790M mutation is under 2 years and there are, as yet, no approved therapies that specifically target this mutation. Therefore, cytotoxic chemotherapy is the current standard of care for such patients.
Further, the T790M gatekeeper mutation has been detected in some patients prior to drug exposure. 17, 18 The frequency of a pre-existing sporadic EGFR T790M mutation has varied widely in the literature: from 2 % to 60 %. 13, [19] [20] [21] [22] [23] [24] [25] In the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy, 98/155 (63 %) had second-site EGFR T790M mutations. 13 The median time to develop drug resistance to EGFR-TKIs has been estimated to be between 6 to 12 months. 26 Median survival is in the region of <2 years after the emergence of T790M. 13 The presence of this mutation before treatment reduces the efficacy of first-generation EGFR-TKIs in patients with EGFR-mutant lung cancer. 22, 24, 25 In this patient population, therefore, it will be beneficial to be able to detect resistant mutations prior to making treatment decisions to enhance personalized therapy.
Two EGFR TKIs, rociletinib (CO-1686; Clovis Oncology, CO, USA) and AZD9291 (AstraZeneca, London, UK), have been shown in preclinical studies to be effective against T790M resistance mutations. 27, 28 Alternative treatments for NSCLC that may be capable of overcoming EGFR T790M mutant-based TKI resistance include allele-specific DNAzyme, such as DzT, and T790M-specific-siRNAs. 29, 30 Rociletinib is an oral, irreversible, potent, covalent inhibitor of the activating EGFR mutations (del19 and L858R) and the T790M resistance mutation, with sparing of wild-type EGFR (see Figure 1 and Table 1) . 27 In xenograft models with EGFR-activating mutations or T790M resistance mutations, rociletinib led to durable tumor shrinkage, especially when plasma concentrations of rociletinib were maintained at more than 200 ng/mL across the doses tested. 27 Given these promising results, a phase I-II (TIGER-X) study was performed. Rociletinib, which has an elimination half-life of 2-4 hours, is Figure 2 ) is evaluating rociletinib in two groups of patients: 31, 32 • patients who have progressed following their first and only EGFRdirected TKI therapy who have developed the T790M mutation; and The study consists of two parts, starting with a phase I dose-escalation study.
In the phase II part of the study, patients with T790M-positive NSCLC received rociletinib 500 mg twice daily (BID), 625 mg BID, or 750 mg BID. In phase I, patients are not restricted to those with T790M-positive status although in phase II, central confirmation of T790M-positive status was required.
The main objectives of TIGER-X are to study the safety and tolerability, pharmacokinetics, and the preliminary anti-tumor activity of rociletinib.
Patient Characteristics
As of April 27, 2015, 456 patients (119 of whom received rociletinib 500 mg BID) were enrolled at 10 centres across the United States, France, and Australia (see Table 2 ). The majority of patients were female (66 %) and n=37 for efficacy evaluable analysis). ORR and DCR based on tissue testing for T790M-negative status using central results (n=37) were 35 % and 65 %, respectively. Response rates for patients with mixed or missing tissue/plasma T790M mutation status are shown in Table 3 . 33, 34 Response rates in patients with centrally confirmed T790M-negative disease and T790M-negative disease by plasma testing were 35 % and 45 %, respectively.
Safety
Common treatment-related adverse events with rociletinib are listed in Table 4 . Acneiform rash was not observed, although one patient had a grade 1 maculopapular rash. 31 No interstitial lung disease was observed in the 500 mg BID dose group; there were 7/456 cases (1.5 %) overall. There Across all dosing levels, a dose-dependent relationship was apparent between rociletinib treatment and hyperglycemia and QTc prolongation. 35 Hyperglycemia is believed to be caused by insulin resistance mediated by a rociletinib metabolite (M502) that inhibits IGF1R/IR. This adverse event was not expected in humans since it was not observed in preclinical studies. Once hyperglycemia was identified, monitoring and treatment guidelines (e.g., monitor blood and/or urine glucose; treat when necessary with oral anti-hyperglycemic agents) was introduced into trial protocols; this approach has been successful in reducing grade ≥3 hyperglycemia in the TIGER-X study. In the 500 mg BID group, nine of 94 patients (9.6 %) without a history of diabetes or glucose impairment had post-baseline glucose measurements that exceeded 250 mg/dL at least two times. Across all three dosing groups (500 mg BID, 625 mg BID, and 750 mg BID), 29 of 382 patients (7.6 %) without a history of diabetes or glucose impairment had post-baseline glucose measurements that exceeded 250 mg/dL at least twice.
Conclusions
In the ongoing TIGER-X study, rociletinib has shown activity in patients with EGFR mutant NSCLC patients associated with the T790M mutation and is well tolerated. Promising activity has also been observed in patients with T790M-negative disease. An ORR of 60 % and DCR of 90 % in centrally confirmed tissue T790M-positive patients were recorded at the 500 mg BID dosing level. The discontinuation rate due to adverse events was low at 2.5 %. The current immature estimates of overall median PFS is 8.0 months in all centrally confirmed tissue T790M-positive patients and 10.3 months in patients without baseline CNS disease. The median number of prior treatments was three for those on the 500 mg BID dose and 82 % of patients had a TKI as their immediate prior line of therapy, which decreases the likelihood or potential of activity being a reflection of an EGFR retreatment effect. ORRs were encouraging among patients with T790M-negative NSCLC; ongoing trials continue to study patients with T790M-negative disease. Possible reasons why we see T790M-negative activity include: tumor heterogeneity, 36 IGF1R signaling, assay sensitivity, and the importance of targeting activating EGFR mutations (del19 and L858R) as opposed to resistance mutation (T790M). TKI retreatment effect is not a likely explanation because the majority of patients had a recent history of progression on an EGFR TKI; immediate EGFR TKI use was also 82 % in all dosing cohorts, ruling out a retreatment effect.
In TIGER-X, 41 % of patients had a history of CNS disease, which is associated with significant morbidity and mortality. 37 Further, only 20 % of the population was of East Asian ethnicity, which may be clinically meaningful because there is evidence from clinical trials that East Asian ethnicity may be a prognostic indicator of response to treatment with EGFR TKIs. 9, 38 In the OPTIMAL study (ClinicalTrials.gov, number NCT00874419), which compared erlotinib with chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer, 100 % of the study population were of Asian ethnicity. The ORR (Response Evaluation Criteria in Solid Tumors [RECIST]) was 82 % and median PFS was 13.1 months. 38 This contrasts with the results of the erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC) study (ClinicalTrials.gov, number NCT00446225), in which 98 % of the population were of Western ethnicity, who, therefore, may be expected to respond to treatment less successfully than the Asian population in the OPTIMAL study. 9 The ORR (RECIST) was 58 % and the median PFS was 9.7 months.
Ongoing TIGER Programme
In addition to the TIGER-X study, rociletinib is being investigated in other lines of therapy. (16) 68(32) 37 (38) 20 (44) 8 (45) 7 (47) 5 (48) 2 (48) 2 (48) 2 (48) 
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New Directions for the TIGER Programme
The TIGER programme is ongoing and a future aim is to investigate whether has not identified a consistent mechanism of resistance. 32 Following further investigation, it may become possible to delay the emergence of a new rociletinib resistance mutation by pairing rociletinib with another agent that targets that specific resistance mechanism. For example, MET amplification is known to occur following use of rociletinib in a minority of cases; therefore, a combination of rociletinib with crizotinib, which targets tumor cells with MET amplification, may be more effective than rociletinib alone.
Other future directions include the investigation of sequencing, combination therapies, and understanding emerging data on mechanisms of resistance, including C797S and MET amplification.
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